Decrease of cyclin D1 in the human lung adenocarcinoma cell line A-427 by 7-hydroxycoumarin.
Coumarin in vivo has antitumor activity in various types of cancer. In vitro, coumarin and 7-hydroxycoumarin, its major biotransformation product in humans, inhibit the proliferation of several human tumor cell lines. The molecular mechanisms of these effects are unknown. To gain information about these mechanisms, we studied the effects of coumarin and 7-hydroxycoumarin in the human lung adenocarcinoma cell line A-427 on the inhibition of: (i) cell proliferation; (ii) cell cycle progression; and (iii) expression of cyclins D1, E and A. The inhibitory concentrations 50 (IC(50)) of both compounds were estimated by cytostatic assays of tetrazolium (MTT) reduction. The effects on cell cycle progression were assayed with propidium iodide and BrdU using DNA histograms and multiparametric flow cytometry. The percentages of cells expressing cyclins D1, E, and A were estimated by means of bivariate flow cytometry using propidium iodide, and FITC-conjugated monoclonal antibodies for each cyclin. The IC(50) (+/-S.E.M. n=3) of 7-hydroxycoumarin and coumarin at 72 h exposure, were 100+/-4.8 and 257+/-8.8 microg/ml, respectively. 7-Hydroxycoumarin at the concentration of 160 microg/ml (1 mM), inhibited the G(1)/S transition of the cell cycle, an action consistent with the cytostatic effect. No significant decreases of cyclins E and A were observed. In contrast, cyclin D1 significantly decreased, which appears to indicate an action of 7-hydroxycoumarin in early events of phase G(1). However, messenger RNA of cyclin D1, assayed by RT-PCR, did not change. This suggests a posttranscriptional effect. The effects of coumarin were not significant. Cyclin D1 is overexpressed in many types of cancer, and its inhibition has been proposed as a pharmacological and therapeutic target for novel antitumor agents. Knowledge of the decrease of cyclin D1 by 7-hydroxycoumarin may lead to its use in cancer therapy, as well as to the development of more active compounds.
Jiménez-Orozco
F A
FA
Departamento de Farmacología, Facultad de Medicina, Universidad Nacional Autónoma de México, Apdo. Postal 70-297 Ciudad Universitaria, Mexico D.F. 04510, Mexico. alejo@servidor.unam.mx
López-González
J S
JS
Nieto-Rodriguez
A
A
Velasco-Velázquez
M A
MA
Molina-Guarneros
J A
JA
Mendoza-Patiño
N
N
García-Mondragón
M J
MJ
Elizalde-Galvan
P
P
León-Cedeño
F
F
Mandoki
J J
JJ
D000230:Adenocarcinoma / Q000473:pathology*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001711:Biotransformation; D002453:Cell Cycle / Q000187:drug effects*; D002455:Cell Division; D003374:Coumarins / Q000494:pharmacology*; D019938:Cyclin D1 / Q000096:biosynthesis*; D004305:Dose-Response Relationship, Drug; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008175:Lung Neoplasms / Q000473:pathology*; D012333:RNA, Messenger / Q000096:biosynthesis; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014407:Tumor Cells, Cultured; D014468:Umbelliferones / Q000494:pharmacology*
D000970:Antineoplastic Agents; D003374:Coumarins; D012333:RNA, Messenger; D014468:Umbelliferones; D019938:Cyclin D1; C031477:7-hydroxycoumarin; C030123:coumarin